Genomes and Genes
female contraceptive agents
Summary: Chemical substances or agents with contraceptive activity in females. Use for female contraceptive agents in general or for which there is no specific heading.
Publications186 found, 100 shown here
- Bleeding problems and progestogen-only contraceptionCharlotte Porter
Victoria Clinic, Nottingham, UK
J Fam Plann Reprod Health Care 28:178-81. 2002
- Advances in hormonal contraceptionNupur Gupta
Tufts University School of Medicine, Boston, MA 02111, USA
Adolesc Med Clin 17:653-71; abstract xi. 2006..The article provides a short description of each of these contraceptive methods, information about compliance, side effects, and efficacy, and an update on that particular method...
- Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093D Heather Watts
National Institute of Child Health and Human Development, NIH, Bethesda, MD 20892, USA
Contraception 77:84-90. 2008..We evaluated the safety and tolerability of depot medroxyprogesterone acetate (DMPA) among women on ARV...
- Experience with the levonorgestrel-releasing intrauterine system among HIV-infected womenPäivi Lehtovirta
Department of Obstetrics and Gynecology, University of Helsinki, SF 00029 Helsinki, Finland
Contraception 75:37-9. 2007..Yet, little is known about LNG-IUS use in HIV-infected women...
- Endometrial effects of intrauterine levonorgestrelAnja Guttinger
Division of Reproductive and Developmental Sciences, The Queen s Medical Research Institute, Centre for Reproductive Biology, The University of Edinburgh, EH16 4TJ Edinburgh, UK
Contraception 75:S93-8. 2007..Much remains to be determined about the mechanisms involved in suppression of menstruation, BTB episodes and the local endometrial environment with local LNG administration...
- Endometrial vessel maturation in women exposed to levonorgestrel-releasing intrauterine system for a short or prolonged period of timeRavet Stéphanie
Laboratory of Tumor and Development Biology, Center of Experimental Cancer Research, University de Liège, Tour de Pathologie B23, Avenue de l Hopital, GIGA R, Sart Tilman, B 4000 Liege, Belgium
Hum Reprod 22:3084-91. 2007..The area, density and maturation of endometrial vessels were quantified in 19 endometrial biopsies of women with LNG-IUS and in 10 normally ovulating patients during mid-luteal phase...
- Health status function after treatment with thermal balloon endometrial ablation and levonorgestrel intrauterine system for idiopathic menorrhagia: a randomized studyWing Hung Tam
Department of Obstetrics and Gynecology, The Chinese University of Hong Kong, Hong Kong, SAR, China
Gynecol Obstet Invest 62:84-8. 2006..To compare patients' health status function after treatment with thermal balloon endometrial ablation (TBEA) and levonorgestrel intrauterine system (LNG-IUS) for idiopathic menorrhagia...
- Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective studyJ M Baeten
Department of Epidemiology, University of Washington, Seattle, WA 98104 2499, USA
Am J Obstet Gynecol 185:380-5. 2001..To examine the relationship between use of oral contraceptive pills or depot medroxyprogesterone acetate and sexually transmitted disease acquisition...
- Prospective clinical trials designed to assess the use of hormonal contraceptives and risk of HIV acquisitionCharles S Morrison
Family Health International, Research Triangle Park, NC, USA
J Acquir Immune Defic Syndr 38:S17-8. 2005
- Randomised comparative trial of thermal balloon ablation and levonorgestrel intrauterine system in patients with idiopathic menorrhagiaRobert W Shaw
Academic Division of Obstetrics and Gynaecology, University of Nottingham, Derby, UK
Aust N Z J Obstet Gynaecol 47:335-40. 2007....
- Hormonal contraceptive use and HIV-1 infection in a population-based cohort in Rakai, UgandaMohammed Kiddugavu
Rakai Project, Uganda Virus Research Institute, Entebbe, Uganda
AIDS 17:233-40. 2003..12 (95% CI, 0.48-2.56) with oral contraceptive use and 0.84 (95%CI, 0.41-1.72) with injectable methods. CONCLUSION: Use of hormonal contraception is not associated with HIV acquisition after adjustment for behavioral confounding...
- The levonorgestrel-releasing intrauterine system (LNG-IUS) in HIV-infected women--effects on bleeding patterns, ovarian function and genital shedding of HIVOskari Heikinheimo
Department of Obstetrics and Gynaecology, University of Helsinki, Finland
Hum Reprod 21:2857-61. 2006..The levonorgestrel-releasing intrauterine system (LNG-IUS) is a highly effective contraceptive with additional health benefits. The objective of this study was to evaluate the effects of the LNG-IUS among HIV-infected women...
- Mifepristone, but not levonorgestrel, inhibits human blastocyst attachment to an in vitro endometrial three-dimensional cell culture modelP G L Lalitkumar
Division of Obstetrics and Gynecology, Department of Woman and Child Health, Karolinska Institutet, Karolinska University Hospital, S 171 76, Stockholm, Sweden
Hum Reprod 22:3031-7. 2007..This study investigates the effect of levonorgestrel and mifepristone on attachment of human embryos to an in vitro endometrial construct...
- Injectable progestin contraceptive use and risk of HIV infection in a South African family planning cohortImmo Kleinschmidt
London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
Contraception 75:461-7. 2007....
- Hormonal contraception and HIV-1 disease progression among postpartum Kenyan womenBarbra A Richardson
Department of Biostatistics, University of Washington, Seattle, WA 98194 2499, USA
AIDS 21:749-53. 2007..To assess the immediate and longer-term effects of the use of hormonal contraception on the progression of HIV-1 disease in postpartum women...
- Development of vaginal rings for sustained release of nonhormonal contraceptives and anti-HIV agentsYoung A Han
Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, Weill Medical College of Cornell University, 515 East 71st Street, S 412, New York, NY 10021, USA
Contraception 76:132-8. 2007..Construction of vaginal rings to deliver nonhormonal contraceptives and 3'-azido-3'-deoxythymidine (AZT) as an anti-HIV agent and determination of their daily release and efficacy in vitro...
- Spinal bone density in women using depot medroxyprogesterone contraceptionT Cundy
Department of Medicine, The Faculty of Medicine and Health Sciences, University of Auckland, New Zealand
Obstet Gynecol 92:569-73. 1998..To determine factors possibly associated with reduced bone density in women using the injectable contraceptive depot medroxyprogesterone acetate...
- A longitudinal study of changes in endometrial microvascular density in Norplant implant usersM Hickey
Sydney Centre for Reproductive Health Research, Department of Obstetrics and Gynaecology, University of Sydney, Australia
Contraception 59:123-9. 1999..The findings suggest that the endometrial vasculature is profoundly altered in the early months of Norplant implant exposure when bleeding problems are most common...
- Superficial endometrial vascular fragility in Norplant users and in women with ovulatory dysfunctional uterine bleedingM Hickey
Department of Reproductive Science and Medicine, Imperial College School of Medicine at St Mary s, Norfolk Place W2 1PG, London, UK
Hum Reprod 15:1509-14. 2000..83, P = 0.01). There was no obvious relationship between subepithelial bleeding and circulating concentrations of oestradiol and progesterone...
- The effect upon the human vaginal histology of the long-term use of the injectable contraceptive Depo-ProveraL Bahamondes
Human Reproduction Unit, Department of Obstetrics and Gynecology, School of Medicine, Universidade Estadual de Campinas, UNICAMP, Campinas, Brazil
Contraception 62:23-7. 2000..In conclusion, the use of Depo-Provera between two and three years did not affect vaginal thinning of the epithelium, Langerhans cell count or maturation index...
- Hormonal contraception and risk of HIV-1 acquisition: results of a 10-year prospective studyLudo Lavreys
Departments of Epidemiology and Medicine, University of Washington, Seattle, WA, USA
AIDS 18:695-7. 2004
- Perivascular smooth muscle alpha-actin is reduced in the endometrium of women with progestin-only contraceptive breakthrough bleedingP A Rogers
Monash University Department of Obstetrics and Gynaecology, Monash Medical Centre, Victoria, Australia
Hum Reprod 15:78-84. 2000....
- Morphological and functional changes in human endometrium following intrauterine levonorgestrel deliveryR L Jones
Prince Henry s Institute of Medical Research, Clayton, Victoria, Australia
Hum Reprod 15:162-72. 2000....
- The long-term actions of etonogestrel and levonorgestrel on decidualized and non-decidualized endometrium in a mouse model mimic some effects of progestogen-only contraceptives in womenNaomi B Morison
Prince Henry s Institute, PO Box 5152, Clayton, Victoria, Australia
Reproduction 133:309-21. 2007..MMP7 was primarily associated with tissue repair. Therefore, this model mimics some of the changes observed in endometria of women using p-only contraceptives and provides an opportunity for functional studies...
- Effects of thrombin, hypoxia, and steroids on interleukin-8 expression in decidualized human endometrial stromal cells: implications for long-term progestin-only contraceptive-induced bleedingCharles J Lockwood
Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, Connecticut 06510, USA
J Clin Endocrinol Metab 89:1467-75. 2004..However, LTPOC-induced hypoxia and excess thrombin generation enhance IL-8 expression in decidualized HESCs, thereby eliciting aberrant angiogenesis and inflammation that promote the onset of abnormal uterine bleeding...
- The Mirena levonorgestrel systemC Jay McGavigan
Department of Obstetrics and Gynecology, Southern General Hospital, South Glasgow University Hospitals NHS Trust, Govan, Glasgow, UK
Drugs Today (Barc) 39:973-84. 2003..Detailed counseling is crucial to explain this anticipated side effect in order to reduce unnecessary discontinuation of treatment...
- Recent developments in hormone delivery systemsLee P Shulman
Department of Obstetrics and Gynecology, Feinberg School of Medicine at Northwestern University, Chicago, IL 60611, USA
Am J Obstet Gynecol 190:S39-48. 2004..Finally, hormonal implants that release low doses of progestins have been used for more than 30 years by a total of 10 million women, and easier-to-use implants will soon be available...
- Relationship between progesterone receptor level in endometrium and bleeding pattern in depot medroxyprogesterone acetate usersPichai Chotnopparatpattara
Department of Obstetrics and Gynaecology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
J Med Assoc Thai 86:172-7. 2003..05). In conclusion, after a second dose of DMPA, subjects with amenorrhea had a higher stromal PR score than those with uterine bleeding...
- Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan womenJared M Baeten
Seattle HIV Prevention Trials Unit, Department of Medicine, University of Washington, 9012 Boren Avenue, Seattle, WA 98104, USA
AIDS 21:1771-7. 2007..A recent study from Uganda and Zimbabwe found that women using hormonal contraception were at increased risk for HIV-1 if they were seronegative for herpes simplex virus type 2 (HSV-2), but not if they were HSV-2 seropositive...
- Pregnancy in effectiveness trials of HIV prevention agentsElizabeth G Raymond
Family Health International, Research Triangle Park, North Carolina, USA
Sex Transm Dis 34:1035-9. 2007
- A three-dimensional study of endometrial microvessels in women using the contraceptive subdermal levonorgestrel implant system, norplantM Simbar
Department of Obstetrics and Gynaecology, Queen Elizabeth II Research Institute for Mothers and Infants, The University of Sydney, Sydney, NSW, 2006, Australia
Micron 35:589-95. 2004....
- The role of tissue factor in regulating endometrial haemostasis: implications for progestin-only contraceptionC J Lockwood
Department of Obstetrics and Gynecology, New York University School of Medicine, NY 10016, USA
Hum Reprod 15:144-51. 2000....
- Abnormal uterine bleeding associated with hormonal contraceptionSarina Schrager
Department of Family Medicine, University of Wisconsin Medical School, Madison 53715, USA
Am Fam Physician 65:2073-80. 2002....
- Hormonal contraception and HIV prevalence in four African countriesPauline M Leclerc
Epidemiologie des Maladies Emergentes, Institut Pasteur, 25 rue du Docteur Roux, Paris, France
Contraception 77:371-6. 2008..The HIV seroprevalence among women aged 15-24 years was compared according to their pattern of contraceptive use in four African countries: Kenya, Lesotho, Malawi and Zimbabwe...
- Contraceptive and therapeutic effects of the levonorgestrel intrauterine system: an overviewJeffrey T Jensen
Department of Obstetrics and Gynecology, UHN 70, Oregon Health and Science University, 3181 Sam Jackson Park Road, Portland, OR 97239, USA
Obstet Gynecol Surv 60:604-12. 2005....
- Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girlsBarbara A Cromer
Department of Pediatrics, MetroHealth Medical Center, Cleveland, OH 44109, USA
J Adolesc Health 35:434-41. 2004....
- Benefit-risk assessment of the levonorgestrel intrauterine system in contraceptionTiina Backman
Department of Obstetrics and Gynecology, Turku University Hospital, Turku, Finland
Drug Saf 27:1185-204. 2004..Thus, the benefits of the levonorgestrel-releasing IUS make it a very suitable method of contraception for most women...
- Relative cost effectiveness of Depo-Provera, Implanon, and Mirena in reversible long-term hormonal contraception in the UKSusan J Varney
CATALYST Health Economics Consultants, Northwood, Middlesex, UK
Pharmacoeconomics 22:1141-51. 2004..Only by offering choice will the maximum number of women be protected and therefore the greatest savings to the health service be gained...
- Expression of vascular endothelial growth factors and their receptors in human endometrium from women experiencing abnormal bleeding patterns after prolonged use of a levonorgestrel-releasing intrauterine systemBjorn Moller
Department of Women s and Children s Health, Uppsala University, Sweden
Hum Reprod 20:1410-7. 2005..The aim of the study was to elucidate the possible association of these VEGF and receptors with bleeding disturbances among users of LNG-IUS...
- What's new in adolescent contraception: what residents and teachers need to knowEduardo Lara-Torre
Kaza Medical Group, Milford, Delaware 19963, USA
J Pediatr Adolesc Gynecol 18:133-5. 2005
- Effect of Norplant contraceptive on the bones of Nigerian women as assessed by quantitative ultrasound and serum markers of bone turnoverDorothy J Vanderjagt
Department of Biochemistry and Molecular Biology, University of New Mexico School of Medicine, Albuquerque, NM 87131-0001, USA
Contraception 72:212-6. 2005..001). We conclude that although levonorgestrel contraceptive decreased overall bone turnover, it had no deleterious effect on the bone quality of women using Norplant implants for up to 4 years...
- Five years' experience with a small intracervical/intrauterine levonorgestrel-releasing devicePaivi Pakarinen
Department of Obstetrics and Gynecology, Helsinki University Central Hospital, 00029 HUS Helsinki, Finland
Contraception 72:342-5. 2005..A randomized study was performed to compare the efficacy, safety and acceptability of a new model of an intracervical/intrauterine contraceptive device (ICD) releasing 20 microg of levonorgestrel (LNG) per day...
- A prospective study of the forearm bone density of users of etonorgestrel- and levonorgestrel-releasing contraceptive implantsLuis Bahamondes
Human Reproduction Unit, Department of Obstetrics and Gynaecology, School of Medicine, Universidade Estadual de Campinas UNICAMP, 13084 971, Campinas, SP, Brazil
Hum Reprod 21:466-70. 2006..The aim of the study was to compare bone mineral density (BMD) before insertion and at 18 months of use of etonorgestrel- and levonorgestrel-releasing contraceptive implants...
- Effective use of hormonal contraceptives: Part II: Combined hormonal injectables, progestogen-only injectables and contraceptive implantsCamaryn E Chrisman
Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA
Contraception 73:125-33. 2006..Norplant implants left in place for up to seven completed years remained effective among women who weighed <70 kg at the time of implant insertion, but their effectiveness decreased among women weighing >or=70 kg...
- Efficacy, acceptability and side effects of the levonorgestrel intrauterine system for menorrhagiaA Kriplani
Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi, India
Int J Gynaecol Obstet 97:190-4. 2007..To evaluate the efficacy, acceptability, and possible side effects of a levonorgestrel-releasing intrauterine system for menorrhagia...
- [Acceptability of intrauterine levonorgestrel delivery system (Mirena 52mg) after estrogen-progesterone oral contraception: results of a prospective multicentric study of 211 patients aged 25-35 years]P Collinet
clinique de gynécologie, Hopital Jeanne de Flandre, CHRU de Lille, 2, Avenue Oscar Lambret, 59037 Lille Cedex
J Gynecol Obstet Biol Reprod (Paris) 35:778-84. 2006..The purpose of this study was to evaluate patient satisfaction among young women during the first year of use of the intrauterine hormonal system...
- Effects of levonorgestrel-releasing IUS and progesterone receptor modulator PRM CDB-2914 on uterine leiomyomasTakeshi Maruo
Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kobe, 650 0017, Japan
Contraception 75:S99-103. 2007..The cell type-specific action of CDB2914 on leiomyoma cells, without affecting the surrounding normal myometrial cells, is meaningful for understanding the usefulness of CDB2914 in the medical treatment of uterine myomas...
- Simultaneous use of a levonorgestrel intrauterine system and an etonogestrel subdermal implant for debilitating adolescent endometriosisMoamar Al Jefout
Department of Obstetrics and Gynaecology, Queen Elizabeth II Research Institute for Mothers and Infants, University of Sydney, New South Wales, Australia
Aust N Z J Obstet Gynaecol 47:247-9. 2007....
- Alternatives to oral regimens of contraceptionM Simon
Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
Minerva Ginecol 59:271-86. 2007....
- Revisiting the intrauterine contraceptive device in adolescentsAlina Toma
Department of Obstetrics and Gynaecology, Queen s University, Kingston, Ontario, Canada
J Pediatr Adolesc Gynecol 19:291-6. 2006....
- Managing drug-resistant essential menorrhagia without hysterectomyRitva Hurskainen
Department of Obstetrics and Gynecology, Hyvinkaa Hospital, Hospital District of Helsinki and Uusimaa, Sairaalank 1, 05850 Hyvinkaa, Finland
Best Pract Res Clin Obstet Gynaecol 20:681-94. 2006..However, second generation ablation techniques may offer better cost-effectiveness than the first generation techniques, but the evidence is insufficient...
- Hormonal contraception: recent advancesAnne Szarewski
Margaret Pyke Centre, London
J Fam Health Care 16:35-6. 2006
- Hormonal contraception and false-positive cervical cytology: is there an association?Anna V Hoekstra
Department of Obstetrics and Gynecology, Illinois Masonic Medical Center, Chicago, USA
J Low Genit Tract Dis 10:102-6. 2006..The aim of the study was to determine if use of hormonal contraception influences the false-positive rate of cervical cytology when compared with loop electrosurgical excision procedure or cervical biopsy specimens...
- Levonorgestrel-releasing intrauterine system vs. transcervical endometrial resection for dysfunctional uterine bleedingB Gupta
Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi, India
Int J Gynaecol Obstet 95:261-6. 2006..To compare the acceptability, efficacy, adverse effects, and user satisfaction of a levonorgestrel intrauterine system (LNG-IUS) and transcervical resection of the endometrium (TCRE) for the treatment of dysfunctional uterine bleeding...
- [Weight variation in users of the levonorgestrel-releasing intrauterine system, of the copper IUD and of medroxyprogesterone acetate in Brazil]Daniela Angerame Yela
Departamento de Obstetricia e Ginecologia, Faculdade de Medicina, Universidade Estadual de Campinas UNICAMP, Campinas, Brazil
Rev Assoc Med Bras 52:32-6. 2006....
- Weight changes in clients on hormonal contraceptives in Zaria, NigeriaSaadatu Sule
Department of Obstetrics and Gynaecology, Ahmadu Bello University Teaching Hospital, Zaria, Nigeria
Afr J Reprod Health 9:92-100. 2005..This information will be beneficial in contraceptive counselling for clients in this environment and provide a baseline for further research...
- The effect of the levonorgestrel intrauterine system on uterine artery blood flow 1 year after insertionA Haberal
Department of Gynecology, S.S.K. Ankara Maternity and Women's Health Teaching Hospital, Ankara, Turkey
Ultrasound Obstet Gynecol 27:316-9. 2006..This increase in RI may have a role in cessation of menstruation...
- Endometrial chemokines, uterine natural killer cells and mast cells in long-term users of the levonorgestrel-releasing intrauterine systemAlessandra Peloggia
Human Reproduction Unit, Department of Obstetrics and Gynaecology, School of Medicine, Universidade Estadual de Campinas (UNICAMP, Campinas, SP, Brazil
Hum Reprod 21:1129-34. 2006..uNK cells and MC products may play a role in provoking breakthrough bleeding in long-term users of the LNG-IUS...
- A study of the capability of manufacturers of generic hormonal contraceptives in lower- and middle-income countriesPeter E Hall
Concept Foundation, Thailand Science Park, Pathumthani 12120, Thailand
Contraception 75:311-7. 2007..Studies were undertaken to assess the capability, competence and capacity of manufacturers of oral and injectable hormonal contraceptives in lower- and middle-income countries...
- Coexpression of fractalkine and its receptor in normal human endometrium and in endometrium from users of progestin-only contraception supports a role for fractalkine in leukocyte recruitment and endometrial remodelingNatalie J Hannan
Prince Henry s Institute of Medical Research, Clayton, Victoria 3168, Australia
J Clin Endocrinol Metab 89:6119-29. 2004..These findings support a number of roles for fractalkine in the endometrium, in the secretory phase, in early pregnancy, and when influenced by progestin-only contraceptives...
- Undiagnosed HIV in women attending a sexual health clinic for non-barrier methods of contraception. Two case studiesMartin Jones
Sexual Health, Eastbourne Sexual Health Clinic, Eastbourne Downs Primary Care Trust, Eastbourne, East Sussex, UK
J Fam Plann Reprod Health Care 29:31-2. 2003..It is suggested that providers of contraception are well placed to identify clients at high risk of HIV and to recommend HIV testing...
- Effects of injectable or implantable progestin-only contraceptives on insulin-glucose metabolism and diabetes riskHenry S Kahn
Division of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia 30341, USA
Diabetes Care 26:216-25. 2003..Additional research could help clarify whether exposure to injectable or implantable contraceptives leads to increased risk of type 2 diabetes and gestational diabetes in women with predisposing factors...
- The local progestational effect of the levonorgestrel-releasing intrauterine system: a sonographic and Doppler flow studyY Zalel
Department of Obstetrics and Gynecology, The Chaim Sheba Medical Center, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Hashomer, Israel
Hum Reprod 17:2878-80. 2002..We aimed to evaluate the effect of the levonorgestrel-releasing intrauterine system (LNG-IUS) on the uterine vasculature and the endometrium...
- New developments in contraceptionL M Keder
College of Medicine, Department of Obstetrics and Gynecology, Ohio State University, Columbus, OH, USA
J Pediatr Adolesc Gynecol 15:179-81. 2002
- Continuous oral or intramuscular medroxyprogesterone acetate versus the levonorgestrel releasing intrauterine system in the treatment of perimenopausal menorrhagia: a randomized, prospective, controlled clinical trial in female smokersT Kucuk
Department of Obstetrics and Gynecology, GATA School of Medicine, Ankara, Turkey
Clin Exp Obstet Gynecol 35:57-60. 2008..To compare the efficacy of three progestin regimens in perimenopausal menorrhagia...
- Clinical experience with Norplant subdermal implant system as long-term contraception during adolescenceE Cardamakis
Department of Obstetrics and Gynecology, University of Patras Medical School, University Hospital, Greece
Eur J Contracept Reprod Health Care 7:36-40. 2002..CONCLUSIONS: This preliminary study has shown that Norplant is acceptable as a contraceptive method among adolescents in Greece and can be prescribed safely...
- Hormonal effects of Depo-Provera in cervical smears: a comparison with Triphasil and postmenopausal effectsStamatina Kaptain
Department of Pathology, St. Joseph's Wayne Hospital, Wayne, New Jersey, USA
Cancer 96:74-82. 2002..The duration of DP use did not appear to have any effect on squamous maturation...
- Recent developments in contraceptive implants at the Population CouncilIrving Sivin
Population Council, Center for Biomedical Research, New York, NY, USA
Contraception 65:113-9. 2002..The status and rationale of studies of a new Nestorone-releasing, single implant developed by the Population Council for a period of use of 2 years are presented...
- Implantable contraceptives for womenOlav Meirik
Instituto Chileno de Medicina Reproductiva, Santiago, Chile
Contraception 65:1-2. 2002
- Progestin-releasing intrauterine systemsT Luukkainen
Steroid Research Laboratory, Institute of Biomedicine, University of Helsinki, Helsinki, Finland
Semin Reprod Med 19:355-63. 2001..Users should be told that the LNG IUS does not prevent sexually transmitted infection, and therefore women at risk should also use condoms for their protection...
- Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifenM D Kesim
Sisli Etfal Research and Training Hospital, 3th Obstetrics and Gynecology Clinic, Istanbul, Turkey
Climacteric 11:252-7. 2008..To investigate the long-term effects of a levonorgestrel-releasing intrauterine system on the endometrium and lipid profile of breast cancer patients taking tamoxifen...
- [Contraception with depot gestagens]D Koryntová
Gynekologicko porodnická klinika VFN a 1 LF UK, Praha
Ceska Gynekol 66:202-8. 2001..Summary of contraceptive implants and injectable contraceptives...
- Intrauterine contraception--what now and what next?J Guillebaud
Margaret Pyke Family Planning Centre, London, UK
Eur J Contracept Reprod Health Care 6:11-4. 2001..Regarding the inconvenience of the first weeks of light post-insertion bleeding and the early-phase low incidence ofsteroidal side-effects, forewarned is forearmed!..
- Effects of levonorgestrel-releasing intra-uterine system on the expression of vascular endothelial growth factor and adrenomedullin in the endometrium in adenomyosisJ B Laoag-Fernandez
Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kobe, Japan
Hum Reprod 18:694-9. 2003..Endometrial angiogenesis is believed to be regulated by angiogenic factors. The study aim was to evaluate the effects of LNg-IUS on vascular endothelial growth factor (VEGF) and adrenomedullin (AM) expression in the endometrium...
- The effects of the levonorgestrel intrauterine system (Mirena coil) on endometrial morphologyV Phillips
Department of Pathology, Royal Group of Hospitals Trust, Grosvenor Road, Belfast BT12 6BL, Northern Ireland, UK
J Clin Pathol 56:305-7. 2003..Pathologists should be aware of these histological features because the Mirena coil is in widespread use...
- A 5-year experience with Norplant implants in Thai womenJ Manonai
Department of Obstetrics and Gynaecology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
Int J Gynaecol Obstet 82:83-4. 2003
- Nondaily hormonal contraception: establishing a fit between product characteristics and patient preferencesJeffrey P Levine
Departments of Family Medicine and Obstetrics, Gynecology and Reproductive Sciences, UMDNJ-Robert Wood Johnson Medical School, 1 RWJ Place, CN19, New Brunswick, NJ 08903-0019, USA
J Fam Pract 53:904-13. 2004
- Effect of etonogestrel subdermal contraceptive implant (Implanon) on liver function tests -- a randomized comparative study with Norplant implantsArijit Biswas
Department of Obstetrics and Gynaecology, National University Hospital, National University of Singapore, 119074, Singapore
Contraception 70:379-82. 2004..The study aimed to assess the possible differences in effects of Implanon and Norplant implants on liver function over 2 years of use...
- Ovarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized studyIngrid J M Duijkers
Dinox Medical Investigations, Groenewoudseweg 317, 6524 TX Nijmegen, The Netherlands
Hum Reprod 19:2668-73. 2004..Due to the different starting procedures, lower ovarian activity was observed in the COC group in the first treatment cycle. In the second cycle, ovarian suppression was comparable with NuvaRing and COC treatment...
- Conceivable sterilization: a constitutional analysis of a Norplant/Depo-Provera welfare conditionKimberly A Smith
Indiana University School of Law-Bloomington, USA
Indiana Law J 77:389-418. 2002
- [A randomized study comparing the efficacy and bleeding pattern of Implanon and Norplant hormonal contraceptive implant]Xiao-ying Yao
Department of Family Planning, Obstetric and Gynecology Hospital, Fudan University, Shanghai 200011, China
Zhonghua Fu Chan Ke Za Zhi 38:419-22. 2003..CONCLUSION: Both contraceptive systems demonstrated excellent contraceptive efficacy and were well tolerated. Because of its single-rod design, Implanon was significantly quicker to insert and remove than the multiple-capsule system...
- The combined contraceptive vaginal ring (NuvaRing) and lipid metabolism: a comparative studyM Tuppurainen
Laboratorio Gyne Oy, Kuopio, Finland
Contraception 69:389-94. 2004..These changes reflect the lower androgenicity of etonogestrel versus levonorgestrel and show that NuvaRing has a minimal effect on lipid profile...
- Successful pregnancy following insertion of a levonorgestrel-releasing intrauterine system in two infertile patients with complex atypical endometrial hyperplasiaXiujuan Qi
Department of Obstetrics and Gynecology, Qingdao University Medical School, Qingdao, PR China
Gynecol Obstet Invest 65:266-8. 2008..Histological morphology of endometrial samples after 6 months' exposure to LNG-IUS showed secretory or atrophic glands with decidualized stroma. Two healthy babies were born following ovulation induction after removal of the LNG-IUS...
- Current treatment of dysfunctional uterine bleedingMarlies Y Bongers
Department of Obstetrics and Gynaecology, Maxima Medical Centre, P O Box 7777, 5500 MB Veldhoven, The Netherlands
Maturitas 47:159-74. 2004..We performed a review of the treatment modalities for dysfunctional uterine bleeding...
- Local levonorgestrel regulation of androgen receptor and 17beta-hydroxysteroid dehydrogenase type 2 expression in human endometriumKevin A Burton
Centre for Reproductive Biology, Chancellor's Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK
Hum Reprod 18:2610-7. 2003..The suppression of AR by the LNG-IUS may also play a role in BTB, as elevated AR has been associated with amenorrhoea...
- The effect of a levonorgestrel-releasing intrauterine system on angiogenic growth factors in the endometriumB A Roopa
Department of Obstetrics and Gynaecology, National University Hospital, National University of Singapore, Singapore
Hum Reprod 18:1809-19. 2003..705, P < 0.015). CONCLUSION: These results provide the first evidence that more than one angiogenic factor could be implicated in aberrant endometrial angiogenesis resulting in breakthrough bleeding in LNG-IUS acceptors...
- Enlarged ovarian follicles in users of a levonorgestrel-releasing intrauterine system and contraceptive implantLuis Bahamondes
Human Reproduction Unit, Department of Obstetrics and Gynecology, School of Medicine, Universidade Estadual de Campinas, Campinas, SP, Brazil
J Reprod Med 48:637-40. 2003....
- Progress in contraception: new technologyEdward S Linn
Department of OB/GYN, Lutheran General Hospital, Park Ridge, Illinois 60068-1174, USA
Int J Fertil Womens Med 48:182-91. 2003..This expanded menu of effective contraceptive options should help women find a method that suits their particular life style...
- The levonorgestrel intrauterine system: a clinical perspective from the UKJohn Guillebaud
University College London and Margaret Pyke Centre, 73 Charlotte Street, London W1T 4PL, UK
Ann N Y Acad Sci 997:185-93. 2003..Regarding the admitted inconvenience of the first weeks of light postinsertion bleeding and the early phase low incidence of steroidal side effects: good counseling is paramount, since forewarned is forearmed!..
- Toxicology of polymers for implant contraceptives for womenPrasad Venkatram Shastri
Department of Materials Science and Engineering and School of Medicine, University of Pennsylvania and Children s Hospital of Philadelphia, Abramson Research Center, Philadelphia, PA, USA
Contraception 65:9-13. 2002..However, any future implant development using these polymers should place an emphasis on processing parameters to minimize potential small molecule leachants and establish safety as a function of both site and duration of implantation...
- Implanon: a new implantable contraceptiveYvonne G Newberry
School of Nursing at the University of Virginia, Charlottesville, VA, USA
Nurs Womens Health 11:607-11. 2007
- Combined hormonal contraception and venous thromboembolismFrancisca Martinez
Institut Universitari Dexeus, Barcelona, Spain
Eur J Contracept Reprod Health Care 12:97-106. 2007....
- Multicenter comparison of the contraceptive ring and patch: a randomized controlled trialMitchell D Creinin
Department of Obstetrics, Gynecology and Reproductive Sciences and Magee Womens Research Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213 3180, USA
Obstet Gynecol 111:267-77. 2008..To understand if the contraceptive ring or patch was more acceptable, as measured primarily by continuation, to women using an oral contraceptive and interested in a nondaily, combined hormonal contraceptive...
- The cost-effectiveness of long-acting reversible contraceptive methods in the UK: analysis based on a decision-analytic model developed for a National Institute for Health and Clinical Excellence (NICE) clinical practice guidelineI Mavranezouli
National Collaborating Centre for Women s and Children s Health NCC WCH, Royal College of Obstetricians and Gynaecologists, London, UK
Hum Reprod 23:1338-45. 2008..However, their uptake is low in much of the developed world. This study aimed at assessing the cost-effectiveness of LARC methods from the British National Health Service (NHS) perspective...
- Do instructions for over-the-counter pre-coital female contraceptives promote "perfect use"?Nikki B Zite
Department of Obstetrics and Gynecology, University of Tennessee Graduate School of Medicine, Knoxville, TN 37920, USA
Contraception 79:211-5. 2009..This study was conducted to estimate the readability and related features of English-language over-the-counter (OTC) pre-coital female contraceptive (PFC) instructions...
- Effect on carbohydrate metabolism and analysis of acceptability (menstrual cycle control) of extended regimens of the vaginally inserted hormone-releasing system 'NuvaRing' as compared with the standard 21/7 regime in reproductive-age women with type 1 diElena E Grodnitskaya
Centre of Family Planning and Reproduction of the Moscow Public Health Department, Moscow, Russia
Gynecol Endocrinol 26:663-8. 2010....
- The contraceptive vaginal ringJill Edwardson
Department of Gynecology and Obstetrics, Johns Hopkins Hospital, Baltimore, Maryland, USA
Semin Reprod Med 28:133-9. 2010..Serious adverse events are rare. In Chile and Peru, progesterone-only vaginal contraceptive rings are available for nursing women. Studies are ongoing examining new formulations of vaginal contraceptive rings...
- Sex education and contraceptive use at coital debut in the United States: results from Cycle 6 of the National Survey of Family GrowthMichelle M Isley
Department of Obstetrics and Gynecology, The Ohio State University, Columbus, OH 43210, USA
Contraception 82:236-42. 2010..The study was conducted to characterize the relationship between formal sex education and the use and type of contraceptive method used at coital debut among female adolescents...
- Surrogate markers, emboldened and boxed warnings, and an expanding culture of misinformation: evidence-based clinical science should guide FDA decision making about product labelingLee P Shulman
Department of Obstetrics and Gynecology, Division of Reproductive Genetics, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
Contraception 73:440-2. 2006
- Evaluating the safety of medicines, with particular reference to contraceptionD C Skegg
Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand
Stat Med 20:3557-69. 2001..In research on contraceptive and drug safety, conclusions usually need to be based on careful assessment of multiple observational studies...
- Induced abortion and unintended pregnancy in GuatemalaSusheela Singh
Guttmacher Institute, New York, USA
Int Fam Plan Perspect 32:136-45. 2006..Recent studies indicate that unsafe abortion is a key factor contributing to maternal morbidity and mortality in the country, but no national data on the incidence of abortion exist...
Research Grants126 found, 100 shown here
- PROGESTERONE & ESTROGEN EFFECTS--SIV VAGINAL TRANSMISSPreston Marx; Fiscal Year: 1999..In addition basic information will be provided on the effects of female reproductive hormones on virus transmission and viral pathogenesis. ..
- Control of menstrual bleeding disturbances in womenIan Fraser; Fiscal Year: 2006..This study aims to explore these possibilities in large scale clinical studies, scientific study of vascular and molecular changes in endometrium and with the exploration of molecular mechanisms in mice. ..
- DEPO-PROVERA USE AND BONE MINERAL DENSITY IN YOUNG WOMENDelia Scholes; Fiscal Year: 2002..The size, diversity, and range of DMPA exposure in this study group allow for comprehensive evaluation of the possibly complex association between this effective, convenient and economical contraceptive and bone mass. ..
- Depo-provera & BMD: Continuing ObservationsM Clark; Fiscal Year: 2005..The longitudinal design will be continued, maintaining all methods and protocols employed in the parent study. ..
- DEPO PROVERA AND BONE MINERAL DENSITY IN ADOLESCENTSBarbara Cromer; Fiscal Year: 2003..The statistical analysis will estimate the effect of DMPA on bone density while taking account of constant treatment discontinuation throughout the study period. ..
- PDE3 Inhibitors: Selective Blockers of Oocyte MaturationJeffrey Jensen; Fiscal Year: 2007..This approach is expected to provide a foundation for future Phase 1 trials of PDE3 inhibitors in humans. ..
- Oral Contraceptive Use and Fractures Around the Menopausal TransitionDelia Scholes; Fiscal Year: 2009..Even a small increase or decrease in fracture resulting from OC use could have important implications for clinical practice and for the public health burden of fracture in women transitioning through menopause and beyond. ..
- Oral Contraceptive Use and Fractures Around the Menopausal TransitionDelia Scholes; Fiscal Year: 2010..Even a small increase or decrease in fracture resulting from OC use could have important implications for clinical practice and for the public health burden of fracture in women transitioning through menopause and beyond. ..
- Oral Contraceptive Use and Bone Density in Young WomenDelia Scholes; Fiscal Year: 2007..abstract_text> ..
- Ectopic Pregnancy: Assessing Long-Term Trends in Rates and Risk FactorsDelia Scholes; Fiscal Year: 2007....
- DEPO-PROVERA AND BONE DENSITY IN PREMENOPAUSAL WOMENM Clark; Fiscal Year: 2003..The menstrual calendar will be collected, reviewed and new calendars provided. Random coefficient regression (RCR) analysis will be the major analytic strategy. ..
- PHI-443: Novel Non-Spermicidal Anti-HIV MicrobicideOSMOND D CRUZ; Fiscal Year: 2003..Specific Aims 1 and 2 may provide the foundation for the clinical development of PHI-443 in Phase II studies as a safe, effective broad-spectrum anti-HIV microbicide without conception-inhibiting functions. ..
- METVAN: A Novel Anticancer AgentOSMOND D CRUZ; Fiscal Year: 2003..The knowledge gained from these studies described under Specific Aims 1-2 is expected to facilitate the design of innovative treatment regimens employing METVAN for metastatic breast cancer and brain tumor patients. ..
- Vanadocenes as a New Class of Spermicidal DrugsOSMOND D CRUZ; Fiscal Year: 2007....
- Stampidine: A Novel Broad-Spectrum Anti-HIV MicrobicideOSMOND D CRUZ; Fiscal Year: 2005..Specific Aims 1 and 2 may provide the foundation for the clinical development of STAMP in Phase II studies as a safe, effective broad-spectrum anti-HIV microbicide without conception-inhibiting functions. ..
- Phase II SBIR: WHI-07: A Novel Dual-Function MicrobicideOSMOND D CRUZ; Fiscal Year: 2005....
- The effect of nonoxynol-9 on human endometriumJohn Jain; Fiscal Year: 2005..The results of this study will provide important preliminary information on the role of microbicides on endometrial toxicity and may help guide future research priorities. ..
- NOVEL CONTRACEPTIVES WITH ANTI-HIV ACTIVITYOSMOND D CRUZ; Fiscal Year: 2001..The preclinical data on in vivo efficacies of WHI-05 and WHI-07 will be essential to further explore the utility of these novel drugs for clinical studies in human patients. ..
- FLP-102: Rationally Engineered Antiviral ProteinOSMOND D CRUZ; Fiscal Year: 2003..The preclinical data on FLP-102 will be essential to further explore the utility of this novel recombinant PAP mutant for Phase II. ..
- PHI 346: A Novel Dual-Function MicrobicideOSMOND D CRUZ; Fiscal Year: 2003..Following successful completion of the Phase I in vivo efficacy studies, gel formulation of PHI-346 will be further explored as a vaginal dual-function microbicide in Phase II. ..
- Prophylactic Ibuprofen: Effect on IUD Continuation RatesDavid Hubacher; Fiscal Year: 2003..In the US, ibuprofen may help spur renewed interest in the most cost effective and efficacious reversible contraceptive method available. ..
- Training in Epidemiology and Clinical Trials (TECT)David Grimes; Fiscal Year: 2007....
- Demography Training at PrincetonJames Trussell; Fiscal Year: 2007....
- Mechanism for Weight Gain In Adolescents on DepoProveaAndrea Bonny; Fiscal Year: 2007..My long-term objective with the proposed training and research plan is to become a national leader on hormonal contraception in adolescents. ..
- Improving contraceptive use/practices among young womenMelissa Gilliam; Fiscal Year: 2007..During the last three years, a qualitative and quantitative pilot study will be conducted among postpartum African American and Latino adolescent girls seeking to avoid a second unintended pregnancy in the year following delivery. ..
- Infrastructure for Population Research at PrincetonJames Trussell; Fiscal Year: 2007..The journal Future of Children will promote effective policies and programs for children by providing policymakers, service providers, and the media with information based on the best available research. ..
- ESTIMATING EFFICACY OF A MEDICAL INTERVENTIONJames Trussell; Fiscal Year: 2001....
- The Role of Prolactin in the Etiology of Postmenopausal Breast CancerShelley Tworoger; Fiscal Year: 2007..This potentially may affect public health by increasing our understanding of how breast cancer develops, which in turn can lead to a better understanding of how to prevent this disease. ..
- Interdisciplinary Mentoring in Women's HealthAbbey Berenson; Fiscal Year: 2007..Ultimately, this plan will allow the trainees to establish independent careers in patient-oriented research. ..
- A Partnership Initiative for HIV Prevention TrialsKathleen M MacQueen; Fiscal Year: 2010..S. South. Improving the capacity for HIV prevention trials in partnership with African American communities will lay the groundwork for moving effective interventions into successful prevention programs. ..
- Membrane Androgen Receptors in NeuroprotectionMeharvan Singh; Fiscal Year: 2007....
- Contraceptive Services/Primary Care to Prevent Birth DefectsEleanor Schwarz; Fiscal Year: 2007....
- A Partnership Initiative for HIV Prevention TrialsKathleen Macqueen; Fiscal Year: 2009..S. South. Improving the capacity for HIV prevention trials in partnership with African American communities will lay the groundwork for moving effective interventions into successful prevention programs. ..
- Dysregulation of IgA responses in HIV-1-infected individualsZdenek Hel; Fiscal Year: 2009....
- Statins & Lymphoid Malignancy Risk in a Large Multi-Site Population-Based CohortMarianne Ulcickas Yood; Fiscal Year: 2010....
- Harnessing Health IT to Prevent Medication-Induced Birth DefectsEleanor Schwarz; Fiscal Year: 2007..In addition, the Health IT intervention shown to be most effective will be disseminated within the University of Pittsburgh Medical Center, which provides 3 million outpatient visits each year...
- Progestin Actions in the Primate Breast and UterusCharles Wood; Fiscal Year: 2007..This work will have immediate public health relevance to postmenopausal women seeking the safest form of hormone therapy. ..
- DOXYCYCLINE FOR BLEEDING IN PROGESTIN ONLY CONTRACEPTORSDavid Archer; Fiscal Year: 2006..If successful, DOX treatment could become an important adjuvant for treatment of this and possibly other inflammatory disorders effecting reproductive tract tissues. ..
- HORMONAL CONTROL OF THE FEMALE REPRODUCTIVE TRACTRobert Brenner; Fiscal Year: 2004..The VEGF family and MMPs during menstrual induction. 2. VEFG-HGF interactions in MMP regulation. 3. KGF-VEGF interactions in spiral artery growth. 4. HGF and VEGF antagonists during menstruation. ..
- COLON CANCER SURVIVORS--MEDICATIONS & RISK OF RECURRENCEChristine Johnson; Fiscal Year: 2004..Using automated pharmacy data, the timing of use and exposure to NSAIDs and HRT will be analyzed among cancer survivors, along with potentially confounding variables, in relation to these outcomes. ..